One in every five reptile species is now threatened with extinction, and that number is growing. The exotic pet trade, habitat loss, and illegal smuggling are all accelerating the collapse — and most people don't even know it's happening because reptiles lack the charisma of pandas or elephants.
Where this was said
At 1:49:40 · chapter starts 1:26:40
Joe Rogan's shock is palpable when Eric Goode walks him through the economics of the turtle trade. Golden coin turtles (Cuora trifasciata) sell for $20,000 to $40,000 each in China, where they are consumed for their alleged medicinal properties — purportedly curing cancer and other diseases. [1] — Eric Goode "Golden coin turtles sell for $20,000 to $40,000 in China. Yunnan box turtles — once thought extinct for 50 years — can fetch $100,000 or mo…" 1:53:10 The Yunnan box turtle, thought extinct for more than half a century and recently rediscovered, commands $100,000 or more. Wild-caught specimens are worth dramatically more than farmed ones because Asian buyers believe wild animals accumulate more medicinal potency from their diet — a logic parallel to wild rhino horn versus farmed horn. Eric describes 15-story turtle farm buildings in China and vast indoor turtle markets where rare US native turtles — wood turtles, spotted turtles, three-toed box turtles from Missouri and Oklahoma — arrive stuffed in socks in luggage, valued at half a million dollars a shipment once they clear customs in Hong Kong. The scale of this trade, Eric argues, eclipses the more visible rhino horn and ivory markets in sheer per-pound value.
One in every five reptile species is now threatened with extinction, a figure that is growing at an accelerating rate driven by the pet trade and smuggling.
The widely shared claim that we have a credit card's worth of plastic in our brains may be a massive overestimate. Researchers used nitrile gloves to measure microplastics — and nitrile gloves shed microplastic particles onto the measuring device. A second paper found the original tool used was unreliable, and that we may have far less plastic than reported.
RSD isn't just hurt feelings — it's a dopamine-deficient brain with a hyperactive amygdala and a frayed connection to the prefrontal cortex. Add a surge of norepinephrine and you get chest pain, sweating, and trembling that convinces your body something catastrophic is happening.
In Dan Ariely's door experiment, participants sacrificed the highest-reward door — repeatedly — just to avoid seeing other doors disappear. Even when researchers trained them to use the best door, they kept wasting clicks to maintain options. This is the bias that runs our lives: we'll take a worse outcome to preserve the feeling of optionality.
Dan Gilbert discovered that the brain has a 'psychological immune system' — it misremembers, reframes, and rationalizes to keep you satisfied with whatever you chose. The fear before commitment is all about potential regret. But after committing, your brain quietly starts justifying the choice — and the more irreversible the decision, the stronger the effect.
The psychological immune system can get you through the first few months of any commitment. But durable, long-term well-being requires self-concordance — choosing commitments that are genuinely aligned with your values and what you actually want. Without that alignment, the satisfaction fades fast.
Vision didn't just help animals find food — it ignited the Cambrian explosion of speciation. Half of the human cortex is devoted to visual processing, and that same visual hierarchy directly inspired the neural network architectures powering today's AI.
Peptides come loaded with a powerful narrative: regenerative, subcutaneous, targeted, cutting-edge. That narrative can genuinely move outcomes, especially for pain, energy, and recovery. The RCT's job is to quantify how much additional benefit comes from the molecule itself — above and beyond the compelling story surrounding it.
A pharmaceutical is not an amino acid sequence — it is the successful solution to manufacturing, purification, formulation, and consistency challenges. When clinical trials prove a drug works, they validate a specific product under specific processes, not every preparation that shares the same sequence.
Ask one question of any peptide advocate: what evidence would prove this claim wrong? If every disappointing result gets attributed to wrong dose, bad supplier, wrong timing, or improper stacking, the hypothesis is not falsifiable — and a non-falsifiable claim is not a scientific claim.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.